ASX ANNOUNCEMENT

22 May 2026

Contract Research Organisation engaged to progress Stabl-Im Phase 1 safety trial

- **Specialist Contract Research Organisation (CRO) Beyond Drug Development has been engaged to progress the planned Phase 1 safety trial for Stabl-Im**
- **Stabl-Im is a proprietary formulation using MRI-based functional imaging designed to visualise tumours without radioactive tracers**
- **Planned Phase 1 study will evaluate the safety and tolerability of Stabl-Im in healthy human volunteers following oral dosing**
- **Initial engagement to advance completion of clinical protocol, regulatory and supporting documentation, and clinical site selection activities**
- **Beyond brings extensive expertise across early-phase clinical development, regulatory strategy and imaging products, with team members averaging 20+ years' experience**
- **Engagement represents an important milestone in advancing Stabl-Im toward Phase 2 efficacy evaluation and broader oncology imaging opportunities**
- **TrivarX is targeting commencement of the Phase 1 safety study during H2 CY26**

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to advise has engaged Beyond Drug Development ("Beyond") to support progression of the Company's planned Phase 1 safety trial for its Stabl-Im imaging technology.

Stabl-Im is TrivarX's proprietary MRI-based functional imaging platform being developed to visualise actively replicating tumour cells using stable isotopes, without the need for radioactive tracers. Stabl-Im is designed to provide earlier and more biologically meaningful insights into tumour activity, cellular proliferation and treatment response. The technology leverages existing MRI infrastructure and has the potential to offer a safer, more accessible and operationally streamlined alternative to traditional imaging techniques across oncology.

Beyond is a boutique therapeutic product development consultancy and contract research organisation (CRO) focused on early-phase product development for biotechnology and pharmaceutical companies globally. The organisation provides strategic, regulatory and clinical development support across a range of innovative therapeutic and diagnostic programs.

Beyond's team brings significant expertise across clinical development, regulatory strategy and early-phase product advancement, with team members averaging more than 20 years' experience. This includes access to specialist regulatory toxicology expertise with over 30 years' experience supporting therapeutic and imaging product development programs.

The initial engagement will focus on supporting completion of the Phase 1 clinical protocol, preparation of supporting clinical and regulatory documentation, and clinical site selection initiatives associated with the planned study.

The proposed Phase 1 trial is expected to be an open-label sequential-cohort study evaluating the safety and tolerability of Stabl-Im in healthy volunteers following oral dosing. The study is intended to generate initial human safety and tolerability data to support progression towards Phase 2 efficacy studies and broader clinical imaging applications.

The engagement forms part of TrivarX's broader strategy to advance Stabl-Im toward clinical development and commercialisation. TrivarX is targeting commencement of the Phase 1 safety study during H2 CY26.

Management commentary:

Incoming CEO, Dr Danielle Meyrick said: *"Engaging Beyond Drug Development represents an important milestone as we progress Stabl-Im through early clinical development and toward future Phase 2 efficacy studies.*

"Importantly, having worked with the group previously, I know firsthand that Beyond brings highly relevant expertise across early-phase clinical development, regulatory strategy and imaging product advancement, which positions the program strongly as we progress toward commencement of the Phase 1 safety study.

"More broadly, Stabl-Im represents a highly differentiated imaging platform with the potential to provide early, clinically meaningful insights into tumour activity and treatment response using a stable isotope tracer. We believe this creates a compelling opportunity across oncology and potentially other potential indications.

"The planned Phase 1 study is expected to generate important human safety and tolerability data and represents a key step toward future efficacy studies, broader clinical development and commercialisation initiatives for the platform.

"With protocol development and broader planning activities now underway, we remain focused on progressing the study toward commencement before the end of CY2026."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About TrivarX Limited:

TrivarX Limited (ASX: TRI) is a healthcare technology company focused on developing innovative diagnostic and imaging solutions across mental health and neuro-oncology. The Company's proprietary technologies include AI-driven algorithms for the detection of mental health conditions using physiological signals, and its Stabl-Im platform, which utilises stable isotope labelling combined with MRI to enable non-invasive imaging of cellular proliferation. Investors can find additional information on www.otcmarkets.com and www.asx.com.au